Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding
Serum Institute of India (SII) is moving to rapidly scale up production of Oxford University's novel Ebola vaccine, backed by an $8.6 million injection from the Coalition for Epidemic Preparedness Innovations (CEPI). This urgent collaboration aims to fast-track clinical trial doses as health authorities grapple with a resurgent Ebola outbreak in Central Africa, leveraging the proven viral vector technology that underpinned the Oxford-AstraZeneca COVID-19 vaccine.











